½ÃÀ庸°í¼­
»óǰÄÚµå
1542887

¼¼°èÀÇ Á¤½Å°Ç°­¿ë µðÁöÅÐ ¾Ë¾à ½ÃÀå(2024-2031³â)

Global Digital Pills for Mental Health Market - 2024-2031

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: DataM Intelligence | ÆäÀÌÁö Á¤º¸: ¿µ¹® 176 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ Á¤½Å°Ç°­¿ë µðÁöÅÐ ¾Ë¾à ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 2¾ï 7,350¸¸ ´Þ·¯¿¡ ´ÞÇϸç, 2024-2031³âÀÇ ¿¹Ãø ±â°£ Áß CAGR 5.6%·Î ¼ºÀåÇϸç, 2031³â¿¡´Â 4¾ï 2,010¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

µðÁöÅÐ ¾Ë¾àÀº Á¤½Å ÇコÄɾ ´ëÇÑ È¹±âÀûÀÎ Á¢±Ù ¹æ½ÄÀ¸·Î, ±â¼ú°ú ¾à¸®ÇÐÀ» °áÇÕÇÏ¿© ¸ÂÃã Ä¡·á¸¦ Á¦°øÇÕ´Ï´Ù. ±âÁ¸ ¾Ë¾à¿¡ ³»ÀåµÈ ÀÌ ¼·Ãë °¡´ÉÇÑ ¼¾¼­´Â º¹¾à ¼øÀÀµµ¿Í »ý¸®Àû ¹ÝÀÀÀ» ¸ð´ÏÅ͸µÇϰí ÀÇ·áÁø¿¡°Ô ½Ç½Ã°£À¸·Î µ¥ÀÌÅ͸¦ Á¦°øÇÕ´Ï´Ù.

ÀÌ Çõ½ÅÀûÀÎ Á¢±Ù ¹æ½ÄÀº Ä¡·á °á°ú¸¦ °³¼±Çϰí, ȯÀÚ Âü¿©µµ¸¦ ³ôÀ̸ç, Á¤½Å°Ç°­ »óŸ¦ °ü¸®ÇÏ´Â µ¥ ÀÖÀ¸¸ç, ±ÍÁßÇÑ ÀλçÀÌÆ®À» Á¦°øÇϰí, º¸´Ù Á¤È®Çϰí ÀûÀÀ·Â ÀÖ´Â Ä¡·á¹ýÀ» ã´Â µ¥ ÀÖÀ¸¸ç, Áß¿äÇÑ ¹ß°ÉÀ½À» ³»µó´Â °ÍÀÔ´Ï´Ù.

½ÃÀå ¿ªÇÐ :

ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎ

Á¤½Å°Ç°­ ÁúȯÀÇ À¯º´·ü »ó½Â

¼¼°è Á¤½Å°Ç°­¿ë µðÁöÅÐ ¾Ë¾à ½ÃÀåÀº Á¤½Å°Ç°­ Àå¾ÖÀÇ À¯º´·ü Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Á¤½Å°Ç°­ Àå¾Ö Áõ°¡´Â ½ÃÀå ¼ºÀåÀÇ Áß¿äÇÑ ¿äÀÎÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Á¤½Å°Ç°­ Àå¾Ö´Â ¹Ì±¹°ú °°Àº ±âÁ¸ ½ÃÀå °æÁ¦ ¹× ¼¼°è ¾ïÁ¦ ¿øÀÎÀÇ »óÀ§±ÇÀ» Â÷ÁöÇϰí ÀÖÀ¸¸ç, ÁÖ¿ä ¿ì¿ïÁõ, ¾ç±Ø¼º Àå¾Ö, Á¤½Å ºÐ¿­Áõ, °­¹Ú Àå¾Ö µîÀ» Æ÷ÇÔÇÕ´Ï´Ù.

¿¹¸¦ µé¾î Á¸½ºÈ©Å²½º ´ëÇÐÀÇ ¹ßÇ¥¿¡ µû¸£¸é 18¼¼ ÀÌ»ó ¹Ì±¹ÀÎÀÇ ¾à 26%, ¼ºÀÎ 4¸í Áß 1¸íÀÌ Áø´Ü °¡´ÉÇÑ Á¤½ÅÀå¾Ö¸¦ ¾Î°í ÀÖ´Â °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

¶ÇÇÑ Á¤½Å°Ç°­Àç´Ü¿¡ µû¸£¸é 2022-2023³â »çÀÌ ¿©¼ºÀº Æò±Õ 37.1%, ³²¼ºÀº Æò±Õ 29.9%°¡ ³ôÀº ¼öÁØÀÇ ºÒ¾ÈÀ» È£¼ÒÇßÀ¸¸ç, 2022³â 7¿ùºÎÅÍ 9¿ù±îÁö 59.4%°¡ ³·Àº ¼öÁØ¿¡¼­ ¸Å¿ì ³·Àº ¼öÁØÀÇ ºÒ¾ÈÀ» °æÇèÇÑ °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ¹Ý¸é, 40.5%´Â 'Áß°£' ¶Ç´Â '³ôÀº' ¼öÁØÀÇ ºÒ¾ÈÀ» °æÇèÇß½À´Ï´Ù.

¶Ç 2022³â WHO¿¡ µû¸£¸é Á¶Çöº´Àº Àü ¼¼°è¿¡¼­ ¾à 2,400¸¸ ¸í, 300¸í Áß 1¸íÀÌ ¾Î°í ÀÖ´Ù°í ÇÕ´Ï´Ù. ÀÌ ºñÀ²Àº ¼ºÀÎ 222 ¸í Áß 1 ¸í¿¡ ÇØ´çÇÕ´Ï´Ù. µû¶ó¼­ À§ÀÇ ¿äÀεéÀÌ ¿¹Ãø ±â°£ Áß ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

µðÁöÅÐ ¾Ë¾à¿¡ ´ëÇÑ µµÀü °úÁ¦

µðÁöÅÐ ¾Ë¾à¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀº ¾î·Æ°í ½Ã°£ÀÌ ¿À·¡ °É¸³´Ï´Ù. Á¦Ç°ÀÇ ¾ÈÀü¼º°ú À¯È¿¼ºÀ» ÀÔÁõÇϱâ À§ÇØ ±â¾÷Àº ´ë±Ô¸ð ÀÓ»ó½ÃÇèÀ» ½Ç½ÃÇØ¾ß ÇϹǷΠ½ÃÀå ÁøÀÔÀÌ Áö¿¬µÉ ¼ö ÀÖ½À´Ï´Ù. µðÁöÅÐ ¾Ë¾àÀ» ÅëÇØ ¹Î°¨ÇÑ °Ç°­ µ¥ÀÌÅͰ¡ ¼öÁýµÇ¹Ç·Î ÇÁ¶óÀ̹ö½Ã ¹× º¸¾È ¹®Á¦°¡ ¹ß»ýÇÕ´Ï´Ù. Á¤º¸ À¯ÃâÀº ȯÀÚ¿Í ±â¾÷ ¸ðµÎ¿¡°Ô ºñÂüÇÑ °á°ú¸¦ ÃÊ·¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼­ À§ÀÇ ¹®Á¦µéÀº ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­

Á¤½Å°Ç°­¿ë µðÁöÅÐ ¾Ë¾à ¼¼°è ½ÃÀåÀº Á¦Ç° À¯Çü, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº°·Î ±¸ºÐµË´Ï´Ù.

¼¾¼­ ³»ÀåÇü µðÁöÅÐ ¾Ë¾à ºÎ¹®ÀÌ ½ÃÀå Á¡À¯À²À» µ¶½ÄÇÒ °ÍÀ¸·Î Àü¸Á

¼¾¼­°¡ ³»ÀåµÈ µðÁöÅÐ ¾Ë¾àÀº Ä¡·á È¿°ú¿Í º¹¾à ¼øÀÀµµ¸¦ Çâ»ó½Ã۱â À§ÇØ ¾à¹°°ú ÷´Ü ±â¼úÀ» ÅëÇÕÇÑ È¹±âÀûÀÎ ÇコÄɾî Çõ½ÅÀÔ´Ï´Ù. ÀÌ ½º¸¶Æ® ¾Ë¾àÀº ¾à¹° ¼·Ãë, ½Åü ¹ÝÀÀ ¹× »ý¸®Àû ÁöÇ¥¿¡ ´ëÇÑ µ¥ÀÌÅ͸¦ ¾ÈÀüÇÑ µðÁöÅÐ Ç÷§ÆûÀ¸·Î Àü¼ÛÇÏ¿© °³ÀÎÈ­µÇ°í ½Ã±âÀûÀýÇÑ °³ÀÔÀ» À§ÇÑ ½Ç½Ã°£ ÀλçÀÌÆ®À» Á¦°øÇÕ´Ï´Ù.

³»ÀåµÈ ¼¾¼­·Î º¹¾à ŸÀ̹ÖÀ» ¸ð´ÏÅ͸µÇÏ¿© º¹¾à ¼øÀÀµµ µ¥ÀÌÅ͸¦ ½Ç½Ã°£À¸·Î Á¦°øÇÕ´Ï´Ù. ÀÇ·á Àü¹®°¡´Â ÀÌ µ¥ÀÌÅ͸¦ ÅëÇØ º¹¾à ¼øÀÀµµ¿¡ ¹®Á¦°¡ ¹ß»ýÇßÀ» ¶§ Á¶Ä¡¸¦ ÃëÇÒ ¼ö ÀÖ½À´Ï´Ù.

ȯÀÚ´Â ¾à¹° »ç¿ë¿¡ ´ëÇÑ Çǵå¹éÀ» ¹ÞÀ» ¼ö ÀÖ´Â ¿É¼ÇÀÌ ÀÖÀ¸¸é ±ÇÀåµÈ Ä¡·á¹ýÀ» ÁؼöÇÒ °¡´É¼ºÀÌ ³ô¾ÆÁý´Ï´Ù. °¢ ȯÀÚº° ¼øÀÀµµ ½À°üÀ̳ª ¾à¹° ¹ÝÀÀ¿¡ µû¶ó µ¥ÀÌÅ͸¦ Ȱ¿ëÇÏ¸é ¸ÂÃãÇü Ä¡·á¹ýÀ» ¼öÁ¤ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀÎÀ¸·Î ÀÎÇØ ÀÌ ºÎ¹®Àº ÇâÈÄ ½ÃÀå Áö¹èÀûÀÎ À§Ä¡¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀå Áö¿ªº° Á¡À¯À²

Á¤½Å°Ç°­¿ë µðÁöÅÐ ¾Ë¾à ½ÃÀå Á¡À¯À²¿¡¼­ ºÏ¹Ì°¡ Å« ºñÁßÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÏ¹Ì´Â Á¤½ÅÁúȯ Áõ°¡, ÷´Ü ÃßÀû ±â¼ú ¹× R&D ÅõÀÚ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø ±â°£ Áß Àüü ½ÃÀå Á¡À¯À²ÀÇ ´ëºÎºÐÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. µðÁöÅÐ ¾Ë¾àÀÇ Ã¤ÅÃÀº Ä¡·á ¼øÀÀµµ¸¦ Çâ»ó½ÃÄÑ È¸º¹ ½Ã°£À» ´ÜÃàÇϰí ÀÌ Áö¿ª ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¿¹¸¦ µé¾î 2021³â ¹Ì±¹ Á¤½ÅÁúȯ¿¬¸Í¿¡ µû¸£¸é ¹Ì±¹ ¼ºÀÎÀÇ ¾à 7.6%°¡ ¹°Áú»ç¿ëÀå¾Ö¿Í Á¤½ÅÁúȯÀ» µ¿½Ã¿¡ ¾Î°í ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù.

µðÁöÅÐ °Ç°­ ±â¼ú ¿¬±¸ ¹× °³¹ßÀº ±â¾÷ÀÌ¿Í ÅõÀÚ È¸»çÀÇ ±¤¹üÀ§ÇÑ Áö¿øÀ» ¹Þ°í ÀÖÀ¸¸ç, ±× °á°ú »õ·Î¿î µðÁöÅÐ ¾Ë¾à Á¦Ç°ÀÇ °ÇÀüÇÑ ÆÄÀÌÇÁ¶óÀÎÀÌ Çü¼ºµÇ°í ÀÖ½À´Ï´Ù. µðÁöÅÐ ¾Ë¾àÀÇ °³¹ß ¹× µµÀÔÀº Á¦¾à ȸ»ç, ±â¼ú ȸ»ç, ÀÇ·á ¼­ºñ½º Á¦°ø ¾÷ü ¹× ¿¬±¸ ±â°üÀÇ Çù·Â¿¡ ÀÇÇØ ÃËÁøµË´Ï´Ù. µû¶ó¼­ À§ÀÇ ¿äÀÎÀ¸·Î ÀÎÇØÀÌ Áö¿ªÀº ½ÃÀå Á¡À¯À²¿¡¼­ Áö¹èÀû ÀÎ À§Ä¡¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå Á¤ÀÇ¿Í °³¿ä

Á¦3Àå °³¿ä

Á¦4Àå ½ÃÀå ¿ªÇÐ

  • ¿µÇâ¿äÀÎ
    • ÃËÁø¿äÀÎ
      • Á¤½Å ÁúȯÀÇ À¯º´·ü »ó½Â
    • ¾ïÁ¦¿äÀÎ
      • µðÁöÅÐ ¾Ë¾à¿¡ °ü·ÃµÈ °úÁ¦
    • ±âȸ
    • ¿µÇ⠺м®

Á¦5Àå »ê¾÷ ºÐ¼®

  • Porter's Five Forces ºÐ¼®
  • °ø±Þ¸Á ºÐ¼®
  • °¡°Ý ºÐ¼®
  • ±ÔÁ¦ ºÐ¼®
  • »óȯ ºÐ¼®
  • ƯÇ㠺м®
  • SWOT ºÐ¼®
  • DMI Àǰß

Á¦6Àå Á¦Ç° À¯Çüº°

  • ¼¾¼­ ³»ÀåÇü µðÁöÅÐ ¾Ë¾à
  • µðÁöÅÐ ¾Ë¾à ³»Àå ¼¾¼­
  • ±âŸ

Á¦7Àå ¿ëµµº°

  • ¿ì¿ïÁõ
  • ºÒ¾ÈÀå¾Ö
  • Á¤½ÅºÐ¿­Áõ
  • Á¶¿ïÁõ
  • ±âŸ

Á¦8Àå ÃÖÁ¾»ç¿ëÀÚº°

  • ÇコÄɾî ÇÁ·Î¹ÙÀÌ´õ
  • Á¦¾àȸ»ç
  • ±âŸ

Á¦9Àå Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ±âŸ À¯·´
  • ³²¹Ì
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ³²¹Ì
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå °æÀï ±¸µµ

  • °æÀï ½Ã³ª¸®¿À
  • ½ÃÀå ÇöȲ/Á¡À¯À² ºÐ¼®
  • ÇÕº´¡¤Àμö ºÐ¼®

Á¦11Àå ±â¾÷ °³¿ä

  • Otsuka America Pharmaceutical, Inc.
  • Idorsia Pharmaceuticals Ltd

Á¦12Àå ºÎ·Ï

KSA 24.09.05

Overview

Global Digital Pills for Mental Health Market reached US$ 273.5 million in 2023 and is expected to reach US$ 420.1 million by 2031, growing at a CAGR of 5.6% during the forecast period 2024-2031.

Digital pills are a revolutionary approach to mental health care, combining technology and pharmacology to offer personalized treatments. These ingestible sensors, embedded within traditional pills, monitor medication adherence and physiological responses, providing real-time data to healthcare providers.

This innovative approach enhances treatment outcomes, improves patient engagement, and offers valuable insights into managing mental health conditions, marking a significant step forward in the quest for more precise and adaptive therapies.

Market Dynamics: Drivers & Restraints

Rise in the prevalence of mental health disorders

The global digital pills for mental health market is driven by the increasing prevalence of mental health disorders. The increasing number of mental health disorders is expected to be a significant factor for the market growth. Mental health disorders account for several of the top causes of disability in established market economies, such as the U.S., and worldwide, and include major depression, bipolar disorder, schizophrenia, and obsessive-compulsive disorder.

For instance, according to a Johns Hopkins University publication, it is estimated that about 26% of Americans ages 18 and older and about 1 in 4 adults suffer from a diagnosable mental disorder.

Additionally, according to the Mental Health Foundation, in 2022-2023, an average of 37.1% of women and 29.9% of men reported high levels of anxiety. From July to September 2022, 59.4% experienced low to very low levels. Whereas 40.5% of people experienced 'medium' or 'high' levels of anxiety.

Also, according to WHO in 2022, Schizophrenia affects approximately 24 million people or 1 in 300 people worldwide. This rate is equal to 1 in 222 people among adults. Thus, the above factors are expected to drive market growth during the forecast period.

Challenges associated with the digital pills

Regulatory clearance for digital tablets can be difficult and time-consuming to obtain. Market entry can get delayed as a result of the substantial clinical trials that companies must do to prove the safety and effectiveness of their products. Sensitive health data is collected via digital pills, which raises privacy and security issues. For both patients and companies, a breach could lead to disastrous consequences. Thus, the above challenges could hamper the market growth.

Market Segment Analysis

The global digital pills for mental health market is segmented based on product type, application, end-user, and region.

Digital pills with embedded sensors segment is expected to dominate the market share

Digital pills with embedded sensors are a revolutionary healthcare innovation that integrates medication with advanced technology to improve treatment efficacy and adherence. These smart pills transmit data about medication ingestion, body response, and physiological metrics to a secure digital platform, providing real-time insights for personalized and timely interventions.

Medication consumption timing is monitored by embedded sensors, which provide adherence data in real-time. Healthcare professionals can take measures when adherence issues arise with the aid of this data.

Patients can be more likely to stick to their recommended regimens if they have the option to obtain feedback regarding their medicine use. Depending on each patient's unique adherence habits and drug responses, the data enables tailored therapy modifications. Thus, the above factors are expected to hold the segment in the dominant position.

Market Geographical Share

North America is expected to hold a significant position in the digital pills for mental health market share

North America is estimated to hold a major portion of the total market share throughout the forecast period owing to factors like advanced tracking technologies and R&D investments, driven by the rise in mental health disorders. The adoption of digital pills improves treatment adherence, leading to faster recovery times and further market growth in the region.

For instance, according to the National Alliance on Mental Illness in 2021, it stated that about 7.6% of U.S. adults experienced a co-occurring substance use disorder and mental illness in 2021

Research and development for digital health technologies is extensively supported by entrepreneurs and investment companies, which results in a healthy pipeline of new digital pill products. The development and implementation of digital pills can be facilitated by collaboration among pharmaceutical corporations, technology businesses, healthcare providers, and research organizations. Thus, the above factors are expected to hold the region in the dominant position in the market share.

Market Segmentation

By Product Type

Digital Pills with Embedded Sensors

Digital Pills Ingestible Sensors

Others

By Application

Depression

Anxiety Disorders

Schizophrenia

Bipolar Disorder

Others

By End-User

Healthcare Providers

Pharmaceutical Companies

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

UK

France

Italy

Spain

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the market include Otsuka America Pharmaceutical, Inc., and Idorsia Pharmaceuticals Ltd among others.

Why Purchase the Report?

To visualize the global digital pills for mental health market segmentation based on product type, application, end-user, and region as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of digital pills for mental health market-level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping available as excel consisting of key products of all the major players.

The global digital pills for mental health market report would provide approximately 53 tables, 47 figures and 176 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise in the prevalence of mental health disorders
    • 4.1.2. Restraints
      • 4.1.2.1. Challenges associated with the digital pills
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Patent Analysis
  • 5.7. SWOT Analysis
  • 5.8. DMI Opinion

6. By Product Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 6.1.2. Market Attractiveness Index, By Product Type
  • 6.2. Digital Pills with Embedded Sensors*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Digital Pills Ingestible Sensors
  • 6.4. Others

7. By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index, By Application
  • 7.2. Depression*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Anxiety Disorders
  • 7.4. Schizophrenia
  • 7.5. Bipolar Disorder
  • 7.6. Others

8. By End-User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.1.2. Market Attractiveness Index, By End-User
  • 8.2. Healthcare Providers*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Pharmaceutical Companies
  • 8.4. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
      • 9.2.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
      • 9.2.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
      • 9.2.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.3.1. U.S.
      • 9.2.3.2. Canada
      • 9.2.3.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
      • 9.3.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
      • 9.3.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.4.1. Germany
      • 9.3.4.2. UK
      • 9.3.4.3. France
      • 9.3.4.4. Italy
      • 9.3.4.5. Spain
      • 9.3.4.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
      • 9.4.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
      • 9.4.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.4.1. Brazil
      • 9.4.4.2. Argentina
      • 9.4.4.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
      • 9.5.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
      • 9.5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.4.1. China
      • 9.5.4.2. India
      • 9.5.4.3. Japan
      • 9.5.4.4. South Korea
      • 9.5.4.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
      • 9.6.2.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
      • 9.6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 9.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Otsuka America Pharmaceutical, Inc.*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Idorsia Pharmaceuticals Ltd (*LIST NOT EXHAUSTIVE)

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦